The U.S. market's high prices create the large profit pool necessary to fund risky drug development. If the U.S. adopted price negotiation like other countries, the global incentive for pharmaceutical innovation would shrink, resulting in fewer new drugs being developed worldwide.

While China is introducing a 7-year orphan drug exclusivity, its impact may be limited. The critical factor for creating a viable market, mirroring the US experience, is the reimbursement environment. The ability to secure high prices for innovative therapies will ultimately determine if China becomes a primary market for orphan drugs.

A disconnect exists between the public rhetoric of U.S. pharma leaders, who frame China's growing biotech sector as a threat, and their corporate actions. These same companies are investing heavily in Chinese R&D and manufacturing, revealing a dual strategy of public caution and private commitment to integrating China into the global biopharma ecosystem.

Through massive government investment in biotech infrastructure, China has become the global hub for early-stage clinical drug development. Both Chinese and Western companies now conduct initial human trials there to move much faster and at a significantly lower cost, giving China a strategic foothold in the pharma value chain.

America's high drug prices, while socially debated, ensure that global biotech innovators, including those in China, prioritize bringing their best drugs to the US market. This guarantees American access to cutting-edge treatments developed anywhere.

Major pharmaceutical companies are now willing to deploy the "nuclear option" of pulling planned R&D investments to express displeasure with national drug pricing policies. This tactic, seen in the UK, represents a direct and aggressive strategy to pressure governments into accepting higher prices for innovative medicines.

Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.

China's government negotiates lower drug prices but then ensures mass adoption, increasing total revenue for pharmaceutical firms. This "win-win" approach contrasts with Western negotiations that typically reduce firm profits, making China a more attractive market for innovation.

Since 2016, China has rapidly reformed its systems, moving from a laggard to the global leader in initiating clinical trials. This lead extends beyond simple volume to pioneering completely new therapies, particularly in areas like cell and gene therapy.